scout
|Videos|March 30, 2017

Dr. Fanale on Challenges Facing Treatments in T-Cell Lymphoma

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

The selection of treatments for patients with T-cell lymphoma is a main challenge that is facing this field, states Fanale. When comparing the new agents, they seem to have an overall response rate of 30% to 40% and have complete remission rates between 15% and 20%.

Many of the ongoing clinical trials in this space are attempting to determine which treatment is more suitable for an individual patient through molecular profiling, explains Fanale.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME